December 12, 2022 - The 208 study was rigorously designed to ensure the stability of an individual’s hearing prior to entering the trial and to exclusively enroll those with the types hearing loss where we observed the strongest hearing improvement in prior FX-322 studies. FX-322 continues to have a favorable ...

October 20, 2021 - Study record managers: refer to the Data Element Definitions if submitting registration or results information

December 16, 2022 - The double-blinded, randomised, placebo-controlled, multicentre trial is intended to assess the efficacy of FX-322 on speech perception in participants aged 18 to 65 years, with hearing loss linked to either noise-induced or permanent idiopathic sudden SNHL.

November 15, 2021 - Pioneering RNA editing to deliver the future of medicine · RNA editing holds great promise to rewrite what’s possible for patients. Since the discovery of the first generation of editing technologies, researchers have been working to overcome the inherent complexity of these initial approaches ...

March 11, 2022 - Frequency Therapeutics is currently conducting a Phase 2b trial to see if a new drug candidate can restore hearing in people who experience sensorineural hearing loss (SNHL).

November 2, 2021 - FX-322 is a new pharmaceutical research drug by Frequency Therapeutics aimed at finding a cure for hearing loss. This article will discuss updates in the drug’s development and its effectiveness in…

February 8, 2023 - In the phase 2a study, Frequency tested the drug, FX-322, in nearly 100 patients with mild to moderate sensorineural hearing loss who had suddenly lost their hearing or have a history of chronic noise exposure. The patients received four weekly injections through their eardrum.

December 9, 2021 - Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s

September 24, 2021 - Frequency Therapeutics, Inc announced that 4 additional SNHL subjects from its FX-322-111 study achieved “statistically significant hearing improvements.”

November 10, 2021 - On Tuesday, the company made several announcements regarding its FX-322 — its drug candidate for hearing loss. Frequency highlighted pooled data from early trials suggesting the product has lead to clinical benefits, and suggested that a Phase 2 study’s discouraging results were due to ...

March 23, 2021 - Frequency Therapeutics’ insistence on carrying on with development of FX-322 despite the hearing loss project having shown precisely no efficacy over placebo in a phase IIa study is doubtless spurred by the lack of any other clinical-stage asset in its pipeline.

FX-322-208 is a Randomized, Placebo-Controlled Study to Evaluate Hearing Improvement in Subjects with Acquired SNHL Company to Host R&D Event on November 9th to Provide Detailed Review of Completed FX-322 Clinical Studies Supporting FX-322-208 Inclusion Criteria and Study Design LEXINGTON, Mass.

October 21, 2021 - Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s